Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation

Cerebral Cavernous Malformations Clinical Trial

Official title: Effect of Oral Propranolol on mRNA Expression in Symptomatice Caavernous Malformation

Status Terminated

Clinical Trial Summary

This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who meet all of the inclusion and exclusion criteria. Patients will be randomized into two groups: A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications, and a Control group of 10 (n=10) patients will receive only their routine medications. Currently, the only active treatment alternative for symptomatic cerebral cavernous malformations is surgery. A control group is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.

Clinical Trial Description

This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who meet all of the inclusion and exclusion criteria. Patients will be randomized into two groups: A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications, and a Control group of 10 (n=10) patients will receive only their routine medications. Currently, the only active treatment alternative for symptomatic cerebral cavernous malformations is surgery. A control group is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group. ;

Related Conditions & MeSH terms

• Cerebral Cavernous Malformations
• Congenital Abnormalities

• NCT number: NCT03474614
• Study type: Interventional
• Source: St. Joseph's Hospital and Medical Center, Phoenix
• Status: Terminated
• Phase: Phase 2
• Start date: January 24, 2018
• Completion date: February 11, 2021